Stanislav Henkin MD , Damon Houghton MD , Andetta Hunsaker MD , Marco Zuin MD , Mariana Pfeferman MD , Alyssa Sato BA , Gregory Piazza MD, MS
{"title":"Artificial Intelligence for Risk Stratification of Acute Pulmonary Embolism: Perspectives on Clinical Needs, Expanding Toolkit, and Pathways Forward","authors":"Stanislav Henkin MD , Damon Houghton MD , Andetta Hunsaker MD , Marco Zuin MD , Mariana Pfeferman MD , Alyssa Sato BA , Gregory Piazza MD, MS","doi":"10.1016/j.amjcard.2025.05.025","DOIUrl":null,"url":null,"abstract":"<div><div>Despite a significant number of innovations for management of acute pulmonary embolism (PE) over the past decade, PE-related mortality has not decreased as expected. Significant heterogeneity in PE presentations and limitations in contemporary risk stratification approaches are hypothesized to be important drivers of poorer than expected outcomes. Recently, artificial intelligence (AI) has gained attention in cardiovascular medicine, notably in wearable technology, electrocardiography, and cardiovascular imaging. The utility of AI has been studied in PE diagnosis and risk stratification, especially in hospitalized patients and has the potential to predict presence of PE based on electrocardiography and clinical risk factors, decrease time to diagnosis, and improve characterization of PE as acute versus chronic. However, AI systems do not appear to have better accuracy in identification of PE compared with radiologists. Additionally, whether utilization of AI in diagnosis and management of PE will improve clinician workflow and patient outcomes remains unknown. In this review, we critically appraise the literature on AI-based strategies to diagnose and refine risk stratification of acute PE and discuss how integration of AI may move the field of PE forward with the universal goal of improving short- and long-term PE-related outcomes.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"252 ","pages":"Pages 40-48"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002914925003340","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Despite a significant number of innovations for management of acute pulmonary embolism (PE) over the past decade, PE-related mortality has not decreased as expected. Significant heterogeneity in PE presentations and limitations in contemporary risk stratification approaches are hypothesized to be important drivers of poorer than expected outcomes. Recently, artificial intelligence (AI) has gained attention in cardiovascular medicine, notably in wearable technology, electrocardiography, and cardiovascular imaging. The utility of AI has been studied in PE diagnosis and risk stratification, especially in hospitalized patients and has the potential to predict presence of PE based on electrocardiography and clinical risk factors, decrease time to diagnosis, and improve characterization of PE as acute versus chronic. However, AI systems do not appear to have better accuracy in identification of PE compared with radiologists. Additionally, whether utilization of AI in diagnosis and management of PE will improve clinician workflow and patient outcomes remains unknown. In this review, we critically appraise the literature on AI-based strategies to diagnose and refine risk stratification of acute PE and discuss how integration of AI may move the field of PE forward with the universal goal of improving short- and long-term PE-related outcomes.
期刊介绍:
Published 24 times a year, The American Journal of Cardiology® is an independent journal designed for cardiovascular disease specialists and internists with a subspecialty in cardiology throughout the world. AJC is an independent, scientific, peer-reviewed journal of original articles that focus on the practical, clinical approach to the diagnosis and treatment of cardiovascular disease. AJC has one of the fastest acceptance to publication times in Cardiology. Features report on systemic hypertension, methodology, drugs, pacing, arrhythmia, preventive cardiology, congestive heart failure, valvular heart disease, congenital heart disease, and cardiomyopathy. Also included are editorials, readers'' comments, and symposia.